Genethon

The biopharma sector has transformed countless lives with innovative therapies, yet an estimated 85-90% of rare diseases lack any approved treatment. The economics of developing new medicines for some

Rare disease has become a real area of focus and growth for drug development. According to Citeline’s Pharma R&D Annual Review 2023 , more than 30% of all drug development is targeted against rar

Genethon may not be a traditional biotech, but as a non-profit it had research and intellectual property incorporated into Novartis AG ’s gene therapy Zolgensma (onasemnogene abeparvovec), and now h

Moderna, Inc. and Merck & Co., Inc. 's* investigational personalized mRNA cancer vaccine, mRNA-4157/V940, has secured a place on the European Medicines Agency’s PRIME (priority medicines) scheme, fo